Accepting new patients
Jonathan Goldman, MD
(he/him)
- Medical Oncology|
- Thoracic Medical Oncology
Santa Monica Cancer Care
|
About
Jonathan W. Goldman, M.D. is a Professor of Medicine at UCLA in the Hematology/Oncology Division. He is the UCLA Director of Clinical Trials in Thoracic Oncology and the Associate Director of Early Drug Development, and the Chair of University of California Lung Cancer Consortium. His research focuses on the development of new treatments for lung and other solid cancers. Most recently he has been investigating novel antibody-drug conjugates, small cell lung cancer therapies, and combination targeted therapies.
Languages
Education
Medical Board Certifications
Hematology, American Board of Internal Medicine, 2008
Medical Oncology, American Board of Internal Medicine, 2008
Internal Medicine, American Board of Internal Medicine, 2004
Fellowship
Hematology & Oncology, UCLA School of Medicine, 2008
Residency
UC San Francisco School of Medicine, 2004
Internship
Internal Medicine, UC San Francisco School of Medicine, 2002
Degree
MD, Stanford University School of Medicine, 2001
Related Clinical Trials
Locations
Hospital Affiliations
Medical Services
Areas of Focus
Videos
Treatment for Lung Cancer
Research
Interests
Lung cancer, targeted therapy, immune therapy.
Publications
- Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 Aug 27;383(9):825-835. doi: 10.1056/NEJMoa2005651. PubMed PMID: 32846061.
- Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Oct 29;383(18):17111723. doi: 0.1056/NEJMoa2027071. Epub 2020 Sep 19. PubMed PMID: 32955177.
- Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJM oa2304594. Epub 2023 Jun 4. PubMed PMID: 37272535.
- Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, Lee CK, Valdiviezo N, Ahmed S, Maurel JM, Andrasina I, Goldman J, Ghiorghiu D, Rukazenkov Y, Todd A, Kobayashi K. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8. PubMed PMID: 37937763.
- Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21. PubMed PMID: 37870976.
Insurance
- Aetna
- Anthem Blue Cross
- Blue Shield of California
- Centivo
- Cigna
- First Health
- Health Net of California
- Interplan (part of HealthSmart)
- Medicare Advantage
- MultiPlan
- UFCM Health System
- Prime Health Services
- Private Healthcare Systems (PHCS)
- TRICARE
- UnitedHealthcare
The list of health care plans above may not be comprehensive and could change.
Please contact your benefits coordinator or health insurance company directly to verify coverage.
Visit our health insurance information page for more details.
Links
Reviews
Dr. Goldman always explains my medical exams and treatment very throughly.
He took his time with me and fully explained results while showing me my CT images.
Dr Goldman is always caring and on top of things Great experience
I’ve been seeing Dr Goldman for almost threes now as he guides me and my husband through this difficult cancer journey. I depend on his knowledge and care and feel safe knowing that he is watching over me. I can’t say enough good things about him. So glad he is my doctor.
As always, clear communication and compassionate care.